Testosterone levels at diagnosis: A key predictor of overall survival among patients with prostate cancer.

• Tác giả: Jarno Aaltonen, Juha P Ahtiainen, Heini Huhtala, Ilkka Jussila, Pirjo Käkelä, Eija K Laakkonen, Koskimaa Mikko, Teemu J Murtola, Ninamaria Onni, Maisa Parviainen, Heikki Pohjolainen, Heikki Seikkula
• Ngôn ngữ: eng
• Thông tin xuất bản: United States : BJUI compass , 2025
• Bộ sưu tập: NCBI
• ID: 186078

Tóm tắt

 BACKGROUND AND OBJECTIVE: The exact relationship between testosterone levels at diagnosis and prostate cancer (PCa) prognosis remains inadequately explored. The objective was to determine whether serum testosterone levels at the time of PCa diagnosis are associated with overall survival. PATIENTS AND METHODS: The study cohort involved 2544 PCa patients, divided into three groups
  normal (>
 10.4 nmol/L), grey zone (8.0-10.4 nmol/L) and low (2.0-8.0 nmol/L) serum testosterone groups. Survival outcomes were analysed using Kaplan-Meier curves and Cox regression models. RESULTS: The analysis revealed an increased risk of death among patients with low testosterone levels compared to those with normal levels in uni- (HR = 1.67, 95% CI: 1.37-2.05, CONCLUSION: Low testosterone at the time of PCa diagnosis is an independent predictor of overall survival. Findings highlight the potential of testosterone for prognostic evaluation in PCa.